Balyasny Asset Management’s Cantel Medical Corporation CMD Stock Holding History

Balyasny Asset Management’s Portfolio CMD Stock Details CMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,647	Closed	-$531K	–	2626
2021 Q1	$531K	Buy	+6,647	New	+$519K	﹤0.01%	1387
2020 Q4	–	Sell	-239,767	Closed	-$10.5M	–	1854
2020 Q3	$10.5M	Buy	239,767 +67,494	+39%	+$3.33M	0.08%	366
2020 Q2	$7.62M	Buy	+172,273	New	+$6.43M	0.07%	403
2020 Q1	–	Sell	-14,458	Closed	-$1.02M	–	1649
2019 Q4	$1.02M	Buy	14,458 +11,245	+350%	+$816K	0.01%	875
2019 Q3	$240K	Buy	+3,213	New	+$272K	﹤0.01%	1053
2018 Q3	–	Sell	-9,586	Closed	-$943K	–	2181
2018 Q2	$943K	Buy	+9,586	New	+$1.07M	﹤0.01%	1153

Balyasny Asset Management's CMD Position: Q2 2021 in Review

Balyasny Asset Management sold out of Cantel Medical Corporation (CMD) in Q2 2021, closing a stake of 6,647 shares — an estimated $531K sold.

Balyasny Asset Management first reported a position in CMD in Q2 2018 and held it in 6 quarters. The position peaked at $10.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold CMD as of Q2 2021.

Balyasny Asset Management reported no remaining Cantel Medical Corporation position as of Q2 2021 after selling out during the quarter.
Balyasny Asset Management sold 6,647 Cantel Medical Corporation shares in Q2 2021, an estimated $531K.
Balyasny Asset Management first reported a position in Cantel Medical Corporation in Q2 2018 and held it in 6 quarters.
Balyasny Asset Management's Cantel Medical Corporation position peaked at $10.5M in Q3 2020.
0 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q2 2021.

Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.